What's the outlook for ASX 200 healthcare shares in FY23?

The share prices of several big names in the ASX 200 healthcare category are strengthening in FY23.

| More on:
Two doctors wearing white coats look closely at a medical imaging x-ray as the share prices of ASX 200 healthcare shares improve in FY23

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • ASX 200 healthcare shares have strengthened in the past month of trade
  • The outlook looks promising with analysts expecting a growth period in healthcare after COVID-19
  • That prognosis looks to be beneficial for ASX 200 healthcare shares 

ASX 200 healthcare shares were a mixed bag in FY22 with many names underperforming their benchmark.

The S&P/ASX 200 Health Care Index (ASX: XHJ) tumbled in December and hasn't made a recovery yet. It's now trading down 7.5% in the year to date.

With the macroeconomic landscape shifting, ASX 200 healthcare shares might be set to catch a bid again.

How's it looking for ASX 200 healthcare shares in FY23?

It appears investors are paying more attention to fundamental analysis in 2022.

For example, unprofitable ASX growth shares and ASX tech shares have been beaten down, whilst profitable ASX mining shares with high free cash flow have soared.

For the healthcare basket, these trends have had a big impact. Healthcare shares have been strengthening in the past month, up 4% in that time.

The sector trades on a price-to-earnings (P/E) ratio of 44.5x per Bloomberg data. Analysts are forecasting average earnings per share (EPS) growth of around 30% for H2 FY22 in the space.

Meanwhile, researchers at Deloitte have weighed in with their opinion on the outlook for the healthcare industry in FY23.

The Deloitte team said that a number of forces are "proving to be the catalyst for the clinical, financial, and operational transformation that health care has long promised to the world".

"Despite COVID-19's many devastating impacts, it does present the health care sector with a powerful opportunity to accelerate innovation and reinvent itself," it added.

Catching a bid in FY23

The stage looks set for large-cap players within the ASX 200 healthcare space to catch a bid in FY23.

We've seen it happen already. Biotech giant CSL Limited (ASX: CSL) has jumped from $269 per share on 1 July to $287.99 now, for instance.

Meanwhile, sleep and respiratory specialist Resmed CDI (ASX: RMD) is up 7% in the past month of trade.

It will be an enduring test for ASX 200 healthcare shares to push through the current market volatility.

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »